AccScience Publishing / ARNM / Online First / DOI: 10.36922/arnm.3499

State of the art in melanoma brain metastatic treatment and evidence of combined high-dose radiotherapy and immunotherapy approach

Silvia Comas Anton1* Gerard Meca Santamaria1 Anabel Mañes Garcia1 Maria Gabriela Antelo Redondo2
Show Less
1 Department of Radiation Oncology, Catalan Institute of Oncology, Badalona, Spain
2 Department of Radiation Oncology, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
Submitted: 25 April 2024 | Accepted: 27 May 2024 | Published: 12 June 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Finding the perfect strategy to treat melanoma brain metastases (BMs) has become a real-world challenge. Despite the difference in response and survival from different primary tumors, multiple guidelines recommend a multidisciplinary approach to treating BM. Although these guidelines are not specific for melanoma BM, most subjects included in the studies on which the guidelines are based are patients with melanoma. One of the strategies for the treatment of melanoma BM that arouses the most interest is the concurrent use of stereotactic radiosurgery and immunotherapy. This strategy seems to be feasible and has shown to improve survival and local control in retrospective series and phase 1 and 2 prospective trials. Here, we present a review of the current recommendations for addressing melanoma BM and the evidence available about the strategy combining focal radiation and immune checkpoint inhibitors.

Melanoma brain metastases
Combined therapy
Stereotactic radiosurgery
Immune checkpoint inhibitors
  1. Diaz MJ, Mark I, Rodriguez D, et al. Melanoma brain metastases: A systematic review of opportunities for earlier detection, diagnosis, and treatment. Life. 2023;13(3):828. doi: 10.3390/life13030828


  1. Phadke M, Ozgun A, Eroglu Z, Smalley KSM. Melanoma brain metastases: Biological basis and novel therapeutic strategies. Exp Dermatol. 2022;31(1):31-42. doi: 10.1111/exd.14286


  1. Rhun EL, Guckenberger M, Smits M, et al. EANOeESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumors. Ann Oncol. 2021;32(11):1332-1347. doi: 10.1016/j.annonc.2021.07.016


  1. Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687-1696. doi: 10.1002/cncr.25634


  1. Kamp MA, Rapp M, Slotty PJ, et al. Incidence of local in-brain progression after supramarginal resection of cerebral metastases. Acta Neurochir (Wien). 2015;157(6):905-910; discussion 910-911. doi: 10.1007/s00701-015-2405-9


  1. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-141. doi: 10.1200/JCO.2010.30.1655


  1. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040-1048. doi: 10.1016/S1470-2045(17)30414-X


  1. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): A multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049-1060. doi: 10.1016/S1470-2045(17)30441-2


  1. Gondi V, Bauman G, Bradfield L, et al. Radiation therapy for brain metastases: An ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12(4):265-282. doi: 10.1016/j.prro.2022.02.003


  1. Schiff D, Messersmith H, Brastianos PK, et al. Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline. J Clin Oncol. 2022;40(20):2271-2276. doi: 10.1200/JCO.22.00333


  1. Yamamoto M, Sato Y, Higuchi Y, Kasuya H, Barfod BE. A cohort study of stereotactic radiosurgery results for patients with 5 to 15 versus 2 to 4 brain metastatic tumors. Adv Radiat Oncol. 2019;5(3):358-368. doi: 10.1016/j.adro.2019.11.001


  1. Lehrer EJ, Peterson JL, Zaorsky NG, et al. Single versus multifraction stereotactic radiosurgery for large brain metastases: An international meta-analysis of 24 trials. Int J Radiat Oncol Biol Phys. 2019;103(3):618-630. doi: 10.1016/j.ijrobp.2018.10.038


  1. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-1437. doi: 10.1093/neuonc/not114


  1. Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III trial NRG oncology CC001. J Clin Oncol. 2020;38(10):1019-1029. doi: 10.1200/JCO.19.02767


  1. Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6


  1. Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722-730. doi: 10.1056/NEJMoa1805453


  1. Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Cancers. 2020;12(3):546. doi: 10.3390/cancers12030546


  1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. doi: 10.1038/nature00766


  1. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1


  1. Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia. 2010;15(4):411-421. doi: 10.1007/s10911-010-9194-9


  1. Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Rezaeyan A, Najafi M. Abscopal effect in radioimmunotherapy. Int Immunopharmacol. 2020;85:106663. doi: 10.1016/j.intimp.2020.106663


  1. Alvarez JI, Saint-Laurent O, Godschalk A, et al. Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions. Neurobiol Dis. 2015;74:14-24. doi: 10.1016/j.nbd.2014.09.016


  1. Procureur A, Simonaggio A, Bibault JE, Oudard S, Vano YA. Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: A comprehensive review and latest developments. Cancers. 2021;13(4):678. doi: 10.3390/cancers13040678


  1. Appelboom G, Detappe A, LoPresti M, et al. Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery. Neuro Oncol. 2016;18(12):1601-1609. doi: 10.1093/neuonc/now137


  1. Petrelli F, De Stefani A, Trevisan F, et al. Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;144:102830. doi: 10.1016/j.critrevonc.2019.102830


  1. He Q, Zhang C, Tang S, Li J, Ren Q. Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: A systematic review and meta-analysis. Transl Cancer Res. 2020;9(10):5909-5924. doi: 10.21037/tcr-20-902


  1. Najafi M, Jahanbakhshi A, Gomar M, et al. State of the Art in combination immuno/radiotherapy for brain metastases: Systematic review and meta-analysis. Curr Oncol. 2022;29(5):2995-3012. doi: 10.3390/curroncol29050244


  1. Su Z, Zhang L, Xue S, Wang Y, Ding R. Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis. Open Life Sci. 2023;18(1):20220559. doi: 10.1515/biol-2022-0559


  1. Kim PH, Suh CH, Kim HS, et al. Immune checkpoint inhibitor with or without radiotherapy in melanoma patients with brain metastases: A systematic review and meta-analysis. Korean J Radiol. 2021;22(4):584. doi: 10.3348/kjr.2020.0728


  1. Trapani S, Manicone M, Sikokis A, et al. Effectiveness and safety of “real” concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: A systematic review. Crit Rev Oncol Hematol. 2019;142:9-15. doi: 10.1016/j.critrevonc.2019.07.006


  1. Chen L, Douglass J, Kleinberg L, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041


  1. Badrigilan S, Meola A, Chang SD, et al. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: A meta-analysis study. Br J Neurosurg. 2023;37(6):1533-1543. doi: 10.1080/02688697.2021.2022098


  1. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368-375. doi: 10.1016/j.ijrobp.2015.01.004


  1. Murphy B, Walker J, Bassale S, et al. Concurrent radiosurgery and immune checkpoint inhibition: Improving regional intracranial control for patients with metastatic melanoma. Am J Clin Oncol. 2019;42(3):253-257. doi: 10.1097/COC.0000000000000509


  1. Qian JM, Yu JB, Kluger HM, Chiang VLS. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016;122(19):3051-3058. doi: 10.1002/cncr.30138


  1. Skrepnik T, Sundararajan S, Cui H, Stea B. Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology. 2017;6(3):e1283461. doi: 10.1080/2162402X.2017.1283461


  1. Le A, Mohammadi H, Mohammed T, et al. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition. J Neurooncol. 2022;158(3):481-488. doi: 10.1007/s11060-022-04038-z


  1. Lehrer EJ, Peterson J, Brown PD, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. Radiother Oncol. 2019;130:104-112.


  1. Nardin C, Mateus C, Texier M, et al. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. Melanoma Res. 2018;28(2):111-119. doi: 10.1097/CMR.0000000000000413


  1. Yusuf MB, Amsbaugh MJ, Burton E, Chesney J, Woo S. Peri-SRS administration of immune checkpoint therapy for melanoma metastatic to the brain: Investigating efficacy and the effects of relative treatment timing on lesion response. World Neurosurg. 2017;100:632-640.e4. doi: 10.1016/j.wneu.2017.01.101


  1. Martin AM, Cagney DN, Catalano PJ, et al. Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol. 2018;4(8):1123-1124. doi: 10.1001/jamaoncol.2017.3993


  1. Koenig JL, Shi S, Sborov K, et al. Adverse radiation effect and disease control in patients undergoing stereotactic radiosurgery and immune checkpoint inhibitor therapy for brain metastases. World Neurosurg. 2019;126:e1399-e1411. doi: 10.1016/j.wneu.2019.03.110


  1. Anvari A, Sasanpour P, Kheradmardi MR. Radiotherapy and immunotherapy in melanoma brain metastases. Hematol Oncol Stem Cell Ther. 2023;16:1-20. doi: 10.1016/j.hemonc.2021.11.001
Conflict of interest
The authors declare that they have no competing interests.
Back to top
Advances in Radiotherapy & Nuclear Medicine, Electronic ISSN: 2972-4392 Published by AccScience Publishing